GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (NAS:SYBX) » Definitions » Current Ratio

Synlogic (Synlogic) Current Ratio : 2.45 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Synlogic Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Synlogic's current ratio for the quarter that ended in Dec. 2023 was 2.45.

Synlogic has a current ratio of 2.45. It generally indicates good short-term financial strength.

The historical rank and industry rank for Synlogic's Current Ratio or its related term are showing as below:

SYBX' s Current Ratio Range Over the Past 10 Years
Min: 2.45   Med: 13.05   Max: 22.23
Current: 2.45

During the past 12 years, Synlogic's highest Current Ratio was 22.23. The lowest was 2.45. And the median was 13.05.

SYBX's Current Ratio is ranked worse than
63.69% of 1556 companies
in the Biotechnology industry
Industry Median: 3.765 vs SYBX: 2.45

Synlogic Current Ratio Historical Data

The historical data trend for Synlogic's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic Current Ratio Chart

Synlogic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.03 12.87 13.23 6.58 2.45

Synlogic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.58 6.40 5.15 4.13 2.45

Competitive Comparison of Synlogic's Current Ratio

For the Biotechnology subindustry, Synlogic's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synlogic's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's Current Ratio distribution charts can be found below:

* The bar in red indicates where Synlogic's Current Ratio falls into.



Synlogic Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Synlogic's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=49.907/20.404
=2.45

Synlogic's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=49.907/20.404
=2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synlogic  (NAS:SYBX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Synlogic Current Ratio Related Terms

Thank you for viewing the detailed overview of Synlogic's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Synlogic (Synlogic) Business Description

Traded in Other Exchanges
Address
301 Binney Street, Suite 402, Cambridge, MA, USA, 02142
Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.
Executives
Michael Vangsted Jensen officer: Chief Financial Officer 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Aoife Brennan officer: Chief Medical Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Antoine Awad officer: Chief Operating Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Michael F. Burgess director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Richard P Shea director C/O MOMENTA PHARMACEUTICALS, INC., 43 MOULTON STREET, CAMBRIDGE MA 02138
Gregg Beloff officer: See Remarks C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Richard J. Riese officer: Chief Medical Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Ginkgo Bioworks, Inc. 10 percent owner 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Scott Eric Plevy officer: Chief Scientific Officer 301 BINNEY STREET, #402, C/O SYNLOGIC, INC., CAMBRIDGE MA 02142
Paul Francis Miller officer: Chief Scientific Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Patricia N. Hurter director C/O SYNLOGIC, INC., 301 BINNEY ST., SUITE 402, CAMBRIDGE MA 02142
Andrew Gengos officer: See Remarks 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Todd Shegog officer: See Remarks 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139